EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -30.77% | -17.39% | +109.29% | -43.73% | -90.82% |
| Gross Profit Growth | -30.09% | -17.33% | +116.46% | -36.01% | -97.50% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +42.01% | +53.09% | +31.85% | +31.43% | +28.87% |
| Weighted Average Shares Diluted Growth | +42.01% | +53.09% | +31.85% | +31.43% | +28.87% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -21.74% | -24.60% | -85.34% | -54.55% | +176.46% |
| Inventory Growth | -38.67% | -40.99% | -49.99% | -27.07% | -24.83% |
| Asset Growth | +88.02% | +17.82% | +10.12% | -7.12% | -16.36% |
| Book Value per Share Growth | +162.75% | -17.47% | -9.45% | -18.01% | -28.98% |
| Debt Growth | +251.15% | +299.67% | +320.87% | -6.35% | -2.83% |
| R&D Expense Growth | +70.14% | +141.61% | +94.35% | +86.10% | +61.65% |
| SG&A Expenses Growth | +17.75% | +10.55% | -1.39% | -7.05% | +11.71% |